Literature DB >> 23189535

What is the difference between prerenal and renal acute kidney injury?

N Lameire, J Van Massenhove, W Van Biesen.   

Abstract

This paper discusses the somewhat artificial distinction between the traditional classification of acute kidney injury in prerenal AKI and established acute tubular necrosis. The primary focus in the setting of a rising SCr should not be assigning the diagnosis of"prerenal" or "renal" AKI but should be determining where the dysfunction lies on the spectrum between purely "functional"and completely structural kidney damage. The new definitions and classification systems of AKI are summarised and the approach to the patient with acute rising serum creatinine and/or acute decline in urinary output is described. The role of the recently introduced novel biomarkers is discussed but it is believed that these biomarkers have not yet proven to be more discriminative in the differential diagnosis between"pure prerenal AKI"and established acute tubular necrosis, beyond a careful clinical evaluation of the patient and the use of the more "traditional" blood and urine parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23189535     DOI: 10.2143/ACB.67.5.2062681

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  3 in total

1.  Understanding oliguria in the critically ill.

Authors:  Miet Schetz; Eric Hoste
Journal:  Intensive Care Med       Date:  2016-09-12       Impact factor: 17.440

2.  Acute Kidney Injury Recognition in Low- and Middle-Income Countries.

Authors:  Jorge Cerdá; Sumit Mohan; Guillermo Garcia-Garcia; Vivekanand Jha; Srinivas Samavedam; Swarnalata Gowrishankar; Arvind Bagga; Rajasekara Chakravarthi; Ravindra Mehta
Journal:  Kidney Int Rep       Date:  2017-04-25

3.  RNA-Seq identifies condition-specific biological signatures of ischemia-reperfusion injury in the human kidney.

Authors:  Meeyoung Park; Chae Hwa Kwon; Hong Koo Ha; Miyeun Han; Sang Heon Song
Journal:  BMC Nephrol       Date:  2020-09-25       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.